Cargando…
Ginsenoside Rg1 treatment protects against cognitive dysfunction via inhibiting PLC–CN–NFAT1 signaling in T2DM mice
BACKGROUND: As a complication of Type II Diabetes Mellitus (T2DM), the etiology, pathogenesis, and treatment of cognitive dysfunction are still undefined. Recent studies demonstrated that Ginsenoside Rg1 (Rg1) has promising neuroprotective properties, but the effect and mechanism in diabetes-associa...
Autores principales: | Dong, Xianan, Kong, Liangliang, Huang, Lei, Su, Yong, Li, Xuewang, Yang, Liu, Ji, Pengmin, Li, Weiping, Li, Weizu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10214300/ https://www.ncbi.nlm.nih.gov/pubmed/37252275 http://dx.doi.org/10.1016/j.jgr.2022.12.006 |
Ejemplares similares
-
Ginsenoside Rg1 alleviates learning and memory impairments and Aβ disposition through inhibiting NLRP1 inflammasome and autophagy dysfunction in APP/PS1 mice
por: Li, Xuewang, et al.
Publicado: (2022) -
Ginsenoside Rg1 treatment alleviates renal fibrosis by inhibiting the NOX4–MAPK pathway in T2DM mice
por: Ji, Pengmin, et al.
Publicado: (2023) -
Ginsenoside Rg1 ameliorates aging-induced liver fibrosis by inhibiting the NOX4/NLRP3 inflammasome in SAMP8 mice
por: Li, Yan, et al.
Publicado: (2021) -
Ginsenoside Rg1 attenuates cerebral ischemia-reperfusion injury due to inhibition of NOX2-mediated calcium homeostasis dysregulation in mice
por: Han, Yuli, et al.
Publicado: (2022) -
Ginsenoside Rg1 alleviates Aβ deposition by inhibiting NADPH oxidase 2 activation in APP/PS1 mice
por: Zhang, Han, et al.
Publicado: (2021)